<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385307</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6607</org_study_id>
    <nct_id>NCT00385307</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)</brief_title>
  <official_title>An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Paroxetine (10 mg qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of Two Fixed Doses of SR58611A (175 mg q12/ 350 mg q12) in Outpatients With MDD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of two fixed doses of SR58611A (175 mg q12 and 350 mg q12) compared
      to placebo in patients with Major Depressive Disorder (MDD) using paroxetine (20 mg qd) as
      positive control. In addition, the tolerability and safety of SR58611A in patients with MDD
      will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in total score of a depression rating scale at 8 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessments</measure>
  </secondary_outcome>
  <enrollment type="Actual">680</enrollment>
  <condition>Major Depressive Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amibegron (SR58611A)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with Major Depressive Disorder diagnosed according to Diagnostic and
             Statistical Manual of Mental Disorders DSM-IV-TR

          -  Patient meets criteria for a recurrent Major Depressive Episode (MDE)

          -  Patient meets severity assessments of depression specified by the study

        Exclusion Criteria:

          -  Patient is at immediate risk for suicidal behavior

          -  Patient is with a unstable medical condition

          -  Patient with psychotic features, catatonic features, seasonal pattern or postpartum
             onset

          -  Patient has taken concomitant treatment that may interfere with valid collection or
             interpretation of study data

          -  Patient has been treated with non-pharmacologic therapy intended to treat depression
             in the past 6 months

          -  Patient has been treated with paroxetine (Paxil) within the previous 6 months

          -  Patient is pregnant or breastfeeding, or likely to become pregnant during the course
             of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2006</study_first_submitted>
  <study_first_submitted_qc>October 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2006</study_first_posted>
  <last_update_submitted>March 24, 2009</last_update_submitted>
  <last_update_submitted_qc>March 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Clinical Trials</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amibegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

